The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Oxidative stress is involved in the aetiopathogenesis of amyotrophic lateral sclerosis (ALS), a fatal degenerative disorder. To test whether oxidative stress in ALS is increased and confined to the central nervous system, we have measured the glycoxidation product N(epsilon)-(carboxymethyl)lysine (CML) in serum and cerebrospinal fluid (CSF) samples by means of a novel enzyme immunoassay. Significant increases of CSF/serum ratio of CML in ALS patients (n = 25) as compared to normal controls (n = 20, p = 0.001) and to Alzheimer disease patients (n = 9, p = 0.029) suggest intrathecal production of this glycoxidation product. Measurement of CML levels may provide a novel diagnostic tool and may supplement current monitoring strategies in interventional trials.
Kaufmann
E
E
Department of Neurology, University of Ulm, Oberer Eselsberg 45, D-89081 Ulm, Germany.
Boehm
B O
BO
Süssmuth
S D
SD
Kientsch-Engel
R
R
Sperfeld
A
A
Ludolph
A C
AC
Tumani
H
H
D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000134:cerebrospinal fluid*; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood / Q000134:cerebrospinal fluid*; D006801:Humans; D008239:Lysine / Q000097:blood / Q000134:cerebrospinal fluid*; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric
D017127:Glycation End Products, Advanced; D008239:Lysine